新型冠状病毒感染相关的甲状腺损害研究进展

徐露佳; 张雨健; 宋雪楠; 张建波; 丛日平; 唐宽晓

doi:10.16766/j.cnki.issn.1674-4152.003932

新型冠状病毒感染相关的甲状腺损害研究进展

doi: 10.16766/j.cnki.issn.1674-4152.003932

1.
山东大学齐鲁医院全科医学科，山东济南 250012
2.
山东大学齐鲁医院急诊科

详细信息

通讯作者:
唐宽晓，E-mail：tangkx_ql@hotmail.com

中图分类号: R581
计量
- 文章访问数: 6
- HTML全文浏览量: 2
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2024-11-07
- 网络出版日期: 2025-05-14

Research progress of infection-related thyroid injury in COVID-19

1.
Department of General Practice, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China

摘要

摘要: 近期相关急性呼吸道感染、肺炎等发病明显增加，仍需警惕新型冠状病毒(coronavirus disease 2019，COVID-19，以下简称新冠病毒)感染。COVID-19可诱导包括甲状腺在内的多器官功能紊乱。COVID-19相关的甲状腺疾病包括：自身免疫性甲状腺炎(autoimmune thyroiditis)、亚急性甲状腺炎(subacute thyroiditis, SAT)、无痛性甲状腺炎(painless thyroiditis)、非甲状腺病态综合征(non-thyroid illness syndrome, NTIS)等。COVID-19导致甲状腺功能异常的机制尚不清楚，新冠病毒疫苗和部分COVID-19治疗药物造成的甲状腺功能变化仍有待研究。本文总结了COVID-19相关甲状腺疾病的国内外研究现状，包括COVID-19相关的甲状腺疾病，COVID-19诱发甲状腺轴功能变化的可能病理生理机制，COVID-19疫苗及治疗药物可能导致的甲状腺功能异常等，旨在优化COVID-19相关甲状腺疾病的诊疗策略、改善预后、降低COVID-19诱发甲状腺疾病的发病率。
- 新型冠状病毒 /
- 甲状腺功能 /
- 甲状腺疾病
Abstract: As a significant increase in the incidence of related acute respiratory infections and pneumonia, highlighting the continued need for vigilance against coronavirus disease 2019 (COVID-19) infection. COVID-19 can induce multiple organ dysfunction, including effects on the thyroid. Thyroid diseases associated with COVID-19 include autoimmune thyroiditis, subacute thyroiditis (SAT), painless thyroiditis, and non-thyroidal illness syndrome (NTIS), etc. However, the mechanisms underlying the abnormal thyroid function caused by COVID-19 remain unclear. Further research is needed to clarify the effects of COVID-19 vaccine and specific therapeutic drugs on thyroid function. This paper summarizes the current research of COVID-19-related thyroid diseases. It covers the spectrum of thyroid diseases associated with COVID-19, the potential pathophysiological mechanisms driving thyroid axis function, and the impact of vaccines and therapeutic drugs on thyroid health. This paper aims to optimize diagnostic and treatment strategies for COVID-19-related thyroid diseases, improve patient prognosis, and reduce the incidence of thyroid disorders induced by COVID-19.
- Coronavirus disease 2019 /
- Thyroid diseases /
- Thyroid function

HTML全文

参考文献(44)

[1]	YUAN Y L, JIAO B H, QU L L, et al. The development of COVID-19 treatment[J]. Front Immunol, 2023, 14: 1125246. DOI: 10.3389/fimmu.2023.1125246.
[2]	李同霞, 邓凯, 林梅, 等. 新型冠状病毒肺炎40例临床特征分析[J]. 青岛大学学报(医学版), 2021, 57(4): 597-600. LI T X, DENG K, LIN M, et al. Clinical features of Coronavirus Disease 2019: an analysis of 40 cases[J]. Journal of Qingdao University (Medical Sciences), 2021, 57(4): 597-600.
[3]	王曦, 安松涛, 李文博, 等. 新型冠状病毒对循环系统影响的研究进展[J]. 中华全科医学, 2021, 19(2): 293-297. doi: 10.16766/j.cnki.issn.1674-4152.001792 WANG X, AN S T, LI W B, et al. Research progress of the effect of SARS-CoV-2 on the circulatory system[J]. Chinese Journal of General Practice, 2021, 19(2): 293-297. doi: 10.16766/j.cnki.issn.1674-4152.001792
[4]	DANESHI S A, TAHERI M, FATTAHI A. SARS coronavirus 2 and central nervous system manifestations: causation, relation, or coexistence? A case series study and literature review[J]. Br J Neurosurg, 2023, 37(5): 1301-1306. doi: 10.1080/02688697.2020.1861433
[5]	MAHALINGASIVAM V, SU G, IWAGAMI M, et al. COVID-19 and kidney disease: insights from epidemiology to inform clinical practice[J]. Nat Rev Nephrol, 2022, 18(8): 485-498. doi: 10.1038/s41581-022-00570-3
[6]	NASA P, ALEXANDER G. COVID-19 and the liver: what do we know so far?[J]. World J Hepatol, 2021, 13(5): 522-532. doi: 10.4254/wjh.v13.i5.522
[7]	GEORGAKOPOULOU V E, AVRAMOPOULOS P, PAPALEXIS P, et al. COVID-19 induced hypoparathyroidism: a case report[J]. Exp Ther Med, 2022, 23(5): 346. DOI: 10.3892/etm.2022.11276.
[8]	KANCZKOWSKI W, EVERT K, STADTMVLLER M, et al. COVID-19 targets human adrenal glands[J]. Lancet Diabetes Endocrinol, 2022, 10(1): 13-16. doi: 10.1016/S2213-8587(21)00291-6
[9]	SCAPPATICCIO L, PITOIA F, ESPOSITO K, et al. Impact of COVID-19 on the thyroid gland: an update[J]. Rev Endocr Metab Disord, 2021, 22(4): 803-815. doi: 10.1007/s11154-020-09615-z
[10]	STEENBLOCK C, RICHTER S, BERGER I, et al. Viral infiltration of pancreatic islets in patients with COVID-19[J]. Nat Commun, 2021, 12(1): 3534. DOI: 10.1038/s41467-021-23886-3.
[11]	TUTAL E, OZARAS R, LEBLEBICIOGLU H. Systematic review of COVID-19 and autoimmune thyroiditis[J]. Travel Med Infect Dis, 2022, 47: 102314. DOI: 10.1016/j.tmaid.2022.102314.
[12]	BRANCATELLA A, RICCI D, VIOLA N, et al. Subacute thyroiditis after Sars-COV-2 infection[J]. J Clin Endocrinol Metab, 2020, 105(7): dgaa276. DOI: 10.1210/clinem/dgaa276.
[13]	MATEU-SALAT M, URGELL E, CHICO A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves ' disease after COVID-19[J]. J Endocrinol Invest, 2020, 43(10): 1527-1528. doi: 10.1007/s40618-020-01366-7
[14]	BRANCATELLA A, VIOLA N, SANTINI F, et al. COVID-induced thyroid autoimmunity[J]. Best Pract Res Clin Endocrinol Metab, 2023, 37(2): 101742. DOI: 10.1016/j.beem.2023.101742.
[15]	BARAJAS GALINDO D E, RAMOS BACHILLER B, GONZÁLEZ ROZA L, et al. Increased incidence of Graves ' disease during the SARS-CoV2 pandemic[J]. Clin Endocrinol (Oxf), 2023, 98(5): 730-737. doi: 10.1111/cen.14860
[16]	中国医师协会中西医结合医师分会内分泌与代谢病学专业委员会, 《桥本甲状腺炎病证结合诊疗指南》编写组. 桥本甲状腺炎病证结合诊疗指南[J]. 中华全科医学, 2024, 22(3): 361-367. doi: 10.16766/j.cnki.issn.1674-4152.003403 Committee of Endocrinology and Metabolism, Society of Integrated Traditional Chinese and Western Medicine Physicians, Chinese Medical Doctor Association, Writing group of Hashimoto ' s thyroiditis disease syndrome combined diagnosis and treatment Guidelines. Guidelines for diagnosis and treatment of Hashimoto ' s thyroiditis with combination of disease and syndrome[J]. Chinese Journal of General Practice, 2024, 22(3): 361-367. doi: 10.16766/j.cnki.issn.1674-4152.003403
[17]	DIXIT N M, TRUONG K P, RABADIA S V, et al. Sudden cardiac arrest in a patient with myxedema coma and COVID-19[J]. J Endocr Soc, 2020, 4(10): bvaa130. DOI: 10.1210/jendso/bvaa130.
[18]	BRANCATELLA A, RICCI D, CAPPELLANI D, et al. Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series[J]. J Clin Endocrinol Metab, 2020, 105(10): dgaa537. DOI: 10.1210/clinem/dgaa537.
[19]	MULLER I, CANNAVARO D, DAZZI D, et al. SARS-CoV-2-related atypical thyroiditis[J]. Lancet Diabetes Endocrinol, 2020, 8(9): 739-741. doi: 10.1016/S2213-8587(20)30266-7
[20]	BATMAN A, YAZICI D, DIKBA Ş O, et al. Subacute THYROiditis related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): a multicenter nationwide study[J]. J Clin Endocrinol Metab, 2023, 108(10): e1013-e1026. DOI: 10.1210/clinem/dgad235.
[21]	DOLKAR T, JITIDHAR F, PATEL M J, et al. Painless subacute thyroiditis in a patient with acute COVID-19 infection: a transient event[J]. Cureus, 2022, 14(7): e26924. DOI: 10.7759/cureus.26924.
[22]	MIZUNO S, INABA H, KOBAYASHI K I, et al. A case of postpartum thyroiditis following SARS-CoV-2 infection[J]. Endocr J, 2021, 68(3): 371-374. doi: 10.1507/endocrj.EJ20-0553
[23]	BESCI T, BESCI Ö, ARSLAN G, et al. Biochemical indicators of euthyroid sick syndrome in critically ill children[J]. J Pediatr Endocrinol Metab, 2022, 35(10): 1285-1292. doi: 10.1515/jpem-2022-0232
[24]	GIOVANELLA L, RUGGERI R M, OVČARIČEK P P, et al. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review[J]. Clin Transl Imaging, 2021, 9(3): 233-240. doi: 10.1007/s40336-021-00419-y
[25]	OKOYE C, NICCOLAI F, ROGANI S, et al. Is non-thyroidal illness syndrome (NTIS) a clinical predictor of COVID-19 mortality in critically ill oldest old patients?[J]. J Endocrinol Invest, 2022, 45(9): 1689-1692. doi: 10.1007/s40618-022-01806-6
[26]	CALCATERRA V, BIGANZOLI G, DILILLO D, et al. Non-thyroidal illness syndrome and SARS-CoV-2-associated multisystem inflammatory syndrome in children[J]. J Endocrinol Invest, 2022, 45(1): 199-208. doi: 10.1007/s40618-021-01647-9
[27]	LUI D T W, LEE C H, WOO Y C, et al. Thyroid dysfunction in COVID-19[J]. Nat Rev Endocrinol, 2024, 20(6): 336-348. doi: 10.1038/s41574-023-00946-w
[28]	FLIERS E, BOELEN A. An update on non-thyroidal illness syndrome[J]. J Endocrinol Invest, 2021, 44(8): 1597-1607. doi: 10.1007/s40618-020-01482-4
[29]	JASINSKI-BERGNER S, SCHMIEDEL D, MANDELBOIM O, et al. Role of HLA-G in viral infections[J]. Front Immunol, 2022, 13: 826074. DOI: 10.3389/fimmu.2022.826074.
[30]	STASIAK M, ZAWADZKA-STARCZEWSKA K, LEWIǸSKI A. Clinical manifestation of subacute thyroiditis triggered by SARS-CoV-2 infection can be HLA-Dependent[J]. Viruses, 2021, 13(12): 2447. DOI: 10.3390/v13122447.
[31]	STASIAK M, ZAWADZKA-STARCZEWSKA K, LEWIǸSKI A. Significance of HLA haplotypes in two patients with subacute thyroiditis triggered by mRNA-Based COVID-19 vaccine[J]. Vaccines (Basel), 2022, 10(2): 280. DOI: 10.3390/vaccines10020280.
[32]	TYWANEK E, MICHALAK A,ŞWIRSKA J, et al. Autoimmunity, new potential biomarkers and the thyroid gland: the perspective of Hashimoto ' s thyroiditis and its treatment[J]. Int J Mol Sci, 2024, 25(9): 4703. DOI: 10.3390/ijms25094703.
[33]	JAEGER M, SLOOT Y J E, HORST R T, et al. Thyrotrophin and thyroxine support immune homeostasis in humans[J]. Immunology, 2021, 163(2): 155-168. doi: 10.1111/imm.13306
[34]	OUDIT G Y, WANG K, VIVEIROS A, et al. Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic[J]. Cell, 2023, 186(5): 906-922. doi: 10.1016/j.cell.2023.01.039
[35]	SHAPIRA T, MONREAL I A, DION S P, et al. ATMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic[J]. Nature, 2022, 605(7909): 340-348. doi: 10.1038/s41586-022-04661-w
[36]	姚小红, 李廷源, 何志承, 等. 新型冠状病毒肺炎(COVID-19)三例遗体多部位穿刺组织病理学研究[J]. 中华病理学杂志, 2020, 49(5): 411-417. doi: 10.3760/cma.j.cn112151-20200312-00193 YAO X H, LI T Y, HE Z C, et al. A pathological report of three COVID-19 cases by minimal invasive autopsies[J]. Chinese Journal of Pathology, 2020, 49(5): 411-417. doi: 10.3760/cma.j.cn112151-20200312-00193
[37]	BARTON L M, DUVAL E J, STROBERG E, et al. COVID-19 Autopsies, Oklahoma, USA[J]. Am J Clin Pathol, 2020, 153(6): 725-733. doi: 10.1093/ajcp/aqaa062
[38]	ZIAKA M, EXADAKTYLOS A. Insights into SARS-CoV-2-associated subacute thyroiditis: from infection to vaccine[J]. Virol J, 2023, 20(1): 132. DOI: 10.1186/s12985-023-02103-1.
[39]	CHEN K, GAO Y Y, LI J. New-onset and relapsed Graves ' disease following COVID-19 vaccination: a comprehensive review of reported cases[J]. Eur J Med Res, 2023, 28(1): 232. DOI: 10.1186/s40001-023-01210-7.
[40]	VOJDANI A, VOJDANI E, KHARRAZIAN D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases[J]. Front Immunol, 2020, 11: 617089. DOI: 10.3389/fimmu.2020.617089.
[41]	国家卫生健康委, 国家中医药局. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 传染病信息, 2023, 36(1): 18-25. doi: 10.3969/j.issn.1007-8134.2023.01.02 National Health Commission, State Administration of Traditional Chinese Medicine. Guideline on diagnosis and treatment of novel coronavirus pneumonia(interim 10th edition)[J]. Infectious Disease Information, 2023, 36(1): 18-25. doi: 10.3969/j.issn.1007-8134.2023.01.02
[42]	LISCO G, DE TULLIO A, JIRILLO E, et al. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects[J]. J Endocrinol Invest, 2021, 44(9): 1801-1814. doi: 10.1007/s40618-021-01554-z
[43]	HUNG I F N. Treatment of coronavirus disease 2019[J]. Curr Opin HIV AIDS, 2020, 15(6): 336-340. doi: 10.1097/COH.0000000000000652
[44]	LUI D T W, TSOI K H, LEE C H, et al. A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors[J]. Endocrine, 2023, 80(2): 380-391. doi: 10.1007/s12020-022-03281-8